Georgia Medicaid does not cover weight loss medication when it’s prescribed only for obesity or weight management. The state uses a federal option that lets Medicaid programs exclude drugs used for weight loss, so GLP-1s like Wegovy, Zepbound, and Saxenda are off the formulary for that purpose. The same drugs are covered when prescribed for other FDA-approved conditions, including type 2 diabetes, cardiovascular disease, and moderate to severe obstructive sleep apnea.1KFF. Medicaid Coverage of and Spending on GLP-1s
What Georgia Medicaid Will Pay For
Federal law requires state Medicaid programs to cover GLP-1 medications when they’re prescribed for an FDA-approved use other than weight loss. In practice, that means a Georgia Medicaid enrollee with the right diagnosis can get coverage for Ozempic (semaglutide) for type 2 diabetes, Wegovy for cardiovascular risk reduction, or Zepbound (tirzepatide) for obstructive sleep apnea in adults with obesity.1KFF. Medicaid Coverage of and Spending on GLP-1s Amerigroup Georgia, one of the state’s managed care plans, lists Wegovy on its formulary with a limit of four pens per 28 days for cardiovascular or MASH indications.2Amerigroup. Quarterly Pharmacy Formulary Change Notice
A few weight-related items do sit on the preferred drug list. Alli (orlistat), a lipase inhibitor, appears under “Anti-Obesity/Anorexiants” and requires prior authorization, a prescription (even though the drug is sold over the counter), and is subject to quantity limits.3Georgia Medicaid. Georgia PDL Imcivree (setmelanotide) is covered with prior authorization, but only for rare genetic obesity disorders such as POMC deficiency, PCSK1 deficiency, LEPR deficiency, and Bardet-Biedl syndrome. General obesity is explicitly excluded from Imcivree coverage.4CareSource. Imcivree Pharmacy Policy Statement
Beyond drugs, Georgia Medicaid covers up to 12 nutritional consultation sessions per year with a licensed dietician, preventive health counseling visits, and bariatric surgery (gastric bypass, gastric band, and sleeve gastrectomy). Bariatric procedures require prior authorization.5GW Stop Obesity Alliance. Medicaid Obesity Coverage – Georgia
Why the Weight Loss Exclusion Exists
The federal Medicaid Drug Rebate Program generally requires state Medicaid programs to cover nearly all FDA-approved medications. But 42 U.S.C. ยง 1396r-8 lets states carve out drugs used for “anorexia, weight loss, or weight gain,” and Georgia uses that exception.1KFF. Medicaid Coverage of and Spending on GLP-1s The Peach State Health Plan preferred drug list spells this out, stating that “drugs prescribed for weight loss” are not covered and are ineligible even for the 72-hour emergency supply provision.6Peach State Health Plan. Preferred Drug List
Cost pressure is the driving force. As of January 2026, only 13 state Medicaid programs cover GLP-1 medications for obesity under fee-for-service, and the group is shrinking. California, New Hampshire, Pennsylvania, and South Carolina all ended their obesity coverage between October 2025 and January 2026.1KFF. Medicaid Coverage of and Spending on GLP-1s
Managed Care Plans and Pathways to Coverage
Georgia’s Medicaid managed care organizations, including Amerigroup, WellCare/CareSource, and Peach State Health Plan, administer the pharmacy benefit for most enrollees. Formularies vary in detail, but the weight-loss exclusion has been described as an “explicit exclusion” rather than a gap individual plans can fill on their own.7Scale Solutions. GLP-1 Cost and Insurance Georgia
Georgia Pathways to Coverage, the state’s limited expansion program for adults aged 19 to 64 who complete 80 hours per month of qualifying activities, follows the same benefit structure. The CareSource Pathways provider manual states that members “are eligible to receive the same State Plan benefits as other Medicaid groups,” with the exception of non-emergency medical transportation.8CareSource. Georgia Pathways to Coverage Provider Manual Addendum Pathways enrollees face the same weight-loss drug exclusion as everyone else on Georgia Medicaid.
Coverage for Children
Federal law requires Medicaid to cover treatments deemed medically necessary for children under the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit. In theory, that could open a route for a child with obesity to receive a GLP-1 even in a state that excludes weight loss drugs for adults.1KFF. Medicaid Coverage of and Spending on GLP-1s No Georgia-specific policy or precedent for covering GLP-1 weight loss medications for children under EPSDT appears in publicly available documentation. The only pediatric obesity drug Georgia Medicaid explicitly covers is Imcivree, and only for the rare genetic conditions listed above.
Options If You’re Paying Out of Pocket
Georgia Medicaid enrollees who want a GLP-1 for weight loss alone have limited options within the program. Several routes exist outside it, each with real restrictions.
Manufacturer patient assistance programs have narrow doors. Novo Nordisk’s Patient Assistance Program can provide medications at no cost to eligible uninsured individuals and some people on Medicare, but Medicaid enrollees are explicitly ineligible and must submit a Medicaid denial letter to apply. Income limits for Ozempic sit at 200% of the federal poverty level.9NovoCare. Patient Assistance Program Eli Lilly’s charitable foundation, Lilly Cares, does not currently list Zepbound.10Find Honest Care. Zepbound Patient Assistance
Direct manufacturer pricing is another route. Eli Lilly sells Zepbound through LillyDirect at $299 to $449 per month depending on dose, with no insurance or income requirements, and the same prices are available at Walmart pharmacies nationwide.11Eli Lilly. Zepbound Savings The TrumpRx program, launched in early 2026 through trumprx.gov, offers a direct-purchase option at roughly $350 per month.10Find Honest Care. Zepbound Patient Assistance These prices remain out of reach for many Medicaid-eligible households.
Compounded semaglutide is often cheaper through telehealth providers, but these products are not FDA-approved and have not been reviewed for safety or effectiveness. The FDA declared the GLP-1 shortage resolved in 2025 and has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which would restrict large-scale compounding. Several major compounding labs stopped production in early 2026, and a public comment period on the proposed restrictions runs through late June 2026. Anyone considering compounded medications is advised to confirm the pharmacy is accredited by the Pharmacy Compounding Accreditation Board or the National Association of Boards of Pharmacy and to request a Certificate of Analysis.12U.S. News. Top GLP-1 Weight Loss Medication Providers
Independent copay grants can help some patients. The PAN Foundation runs an obesity medication copay grant program, though applicants must already have insurance that covers the qualifying medication.13PAN Foundation. Obesity Disease Fund NeedyMeds and RxAssist (rxassist.org) maintain broader directories of patient assistance programs.14P2P Georgia. Patient Assistance Programs
Federal Changes That Could Shift Georgia’s Coverage
Two federal moves could change the picture. In December 2024, CMS under the Biden administration proposed a rule (CMS-4208-P) that would have reinterpreted the statutory exclusion and required Medicaid programs to cover anti-obesity medications. The National Association of Medicaid Directors opposed it, citing projected costs of $30 million to $79 million annually for small states and $50 million to $126 million for medium-sized states.15National Association of Medicaid Directors. Optional, Not Mandatory: NAMD Recommendations on Anti-Obesity Medication Coverage On April 4, 2025, CMS announced it was “not finalizing” that provision, shelving the mandate.16CMS. Contract Year 2026 Policy and Technical Changes Final Rule Fact Sheet
The Trump administration launched a different approach in December 2025: the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) model, a voluntary five-year program through the CMS Innovation Center. Under BALANCE, CMS negotiates lower GLP-1 prices with manufacturers on behalf of participating state Medicaid agencies. The model sets standardized coverage criteria and ties clinical eligibility to BMI thresholds of 27, 30, or 35 and above combined with specific comorbidities like type 2 diabetes, heart failure, uncontrolled hypertension, chronic kidney disease, or MASH.17CMS. BALANCE Model State participation opened in May 2026 and the model runs through December 2031. Whether Georgia will opt in is not yet known.